MYC and ovarian cancer: Recently, 2-[[(5-bromo-2-thienyl)methylene]amino]-benzamide (BTYNB) was identified as a selective inhibitor of CRD-BP binding to the CRD region of MYC mRNA thereby increasing MYC turnover in melanoma and ovarian cancer cells [61].